$18.97
+0.40%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$19.10
From 52W high−54.25%
Volume200080.00
Market cap$2.27B
P/E (TTM)—
P/S (TTM)87.7x
Div yield—
Key dataNov 6, 2026
Open
$19.10
From 52W high
−54.25%
Volume
200080.00
Market cap
$2.27B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.1x
P/E (TTM)
—
RSI (14)
41.4
MomentumView details →
1D Return
+0.40%
YTD Return
−43.93%
SummaryUpdated Sep 1, 2026
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands. The company went public in February 2021 and focuses on developing innovative treatments for metabolic diseases, particularly cardiovascular conditions related to cholesterol management. NewAmsterdam's primary focus is advancing its lead drug candidate through clinical trials to address unmet medical needs in cholesterol treatment and cardiovascular disease prevention.
Similar companies
Latest newsMore news →
NewAmsterdam Pharma Co N.V. reported a third-quarter loss of $0.14 per share, compared with the Zacks Investment Research, Inc. Consensus Estimate of a $0.50 loss per share.2d agoNewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in adults with biomarker evidence of preclinical Alzheimer's disease.38d ago